



Revance Therapeutics
Investor Relations Department
7555 Gateway Boulevard
Newark, CA 94560
United States

Visit IR website [↗](#)
Sign-up for Email alerts [↗](#)

NASDAQ: RVNC

Last Trade:	24.10
Trade Time:	1:10 PM ET Sep 19, 2017
Change:	-0.30 ↓ (-1.230%)
Day Range	23.71 - 24.55
52-Week Range	12.35 - 28.30
Volume	71,330


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Revance, a Silicon Valley-based biotechnology company, is committed to the advancement of remarkable science. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance's science is based upon a proprietary TransMTS® peptide technology, which, when combined with active drug molecules, may help address current unmet needs.

Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthe... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Sep 6, 2017 [Revance Appoints Mark Foley to its Board of Directors](#)
- Aug 30, 2017 [Revance to Participate in the 2017 Wells Fargo Securities Healthcare Conference](#)
- Aug 3, 2017 [Revance Releases Second Quarter 2017 Results](#)
- Aug 2, 2017 [Revance Therapeutics Expands Leadership Team, Appointing Todd Zavodnick Chief Commercial Officer and President, Aesthetics & Therapeutics](#)
- Aug 1, 2017 [Revance Therapeutics Expands Leadership Team, Appointing Todd Zavodnick Chief Commercial Officer and President, Aesthetics & Therapeutics](#)

Financials [\[View all \]](#)

- [Second Quarter Financial Results](#)
- Feb 28, 2017 [Annual Report \(10-K\)](#)
- Mar 24, 2017 [Proxy Statement \(DEF 14A\)](#)
- Aug 4, 2017 [Quarterly Report \(10-Q\)](#)
- May 9, 2017 [Quarterly Report \(10-Q\)](#)
- Nov 4, 2016 [Quarterly Report \(10-Q\)](#)